Psoriasis treatment patterns: Results of a cross-sectional survey of dermatologists

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 964-969

  Patel, Vaishali ^a   Horn, Elizabeth J ^b,c   Lobosco, Steve J ^d   Fox, Kathleen M ^e   Stevens, Seth R ^a   Lebwohl, Mark ^f  

^a AMGEN INC   (United States)

^b National Psoriasis Foundation   (United States)

^c International Psoriasis Council   (United States)

^d ADELPHI REAL WORLD   (United Kingdom)

^e Strategic Healthcare Solutions LLC   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; DONOVEX; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PSORALEN; RETINOID DERIVATIVE; TACROLIMUS; TAZAROTENE;

ADULT; ARTICLE; BODY SURFACE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME;

CROSS-SECTIONAL STUDIES; DERMATOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 43249086678     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.02.048     Document Type: Article

References (14)

1. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., and Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
2. Gupta M.A., and Gupta A.K. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 34 (1995) 700-703
3. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstad T., and Margolis D.J. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51 (2004) 704-708
4. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., and Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 37 (2001) 280-284
5. Mallbris L., Ritchlin C.T., and Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8 (2006) 355-363
6. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4 (2003) 441-447
7. Lebwohl M., and Ali S. Treatment of psoriasis, part 1: topical therapy and phototherapy. J Am Acad Dermatol 45 (2001) 487-498
8. Lebwohl M., and Ali S. Treatment of psoriasis, part 2: systemic therapies. J Am Acad Dermatol 45 (2001) 649-661
9. Griffiths C.E. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 359 (2002) 279-280
10. Callen J.P., Krueger G.G., Lebwohl M., McBurney E.I., Mease P., Menter A., et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 49 (2003) 897-899
11. Koo J.Y. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 26 (1999) 723-733
12. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D., et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153 (2005) 486-497
13. Horn E.J., Fox K.M., Patel V.D., Chiou C., Dann F., and Lebwohl M. Are psoriasis patients under-treated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 57 (2007) 957-962
14. Roberts J., and Williams A. Quality-of-life and asthma control with low-dose inhaled corticosteroids. Br J Nurs 13 (2004) 1124-1129